Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803654 | 0.76 | CA1 (0.31) | CA1CA2CA12CA7CA9 | |
| SCHEMBL20043145 | 0.71 | — | — | |
| SCHEMBL890639 | 0.69 | PYGM (0.52) | PYGM | |
| SCHEMBL13657660 | 0.69 | — | — | |
| SCHEMBL4827962 | 0.69 | PYGM (0.43) | PYGM | |
| SCHEMBL14302870 | 0.68 | KDM4E (0.31) | — | |
| SCHEMBL16749889 | 0.67 | — | — | |
| SCHEMBL16749888 | 0.67 | — | — | |
| SCHEMBL15457433 | 0.62 | LMNA (0.39) | CA1CA2CA12CA7CA9 | |
| SCHEMBL14502255 | 0.62 | SMN1; SMN2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980938-B2 | CXCR2 inhibitors | SANOFI (FR) | 2015-03-17 | — | — | US | disclosed |
| US-8642643-B2 | CXCR2 antagonists | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20090258906-A1 | CXCR2 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| US-20090258936-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258936-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | PYGM 3027/4885CA1 1572/4885CA2 745/4885 |
| US-20090258906-A1 | CXCR2 ANTAGONISTS | CXCR2, CXCR1, CXCR3 | PYGM 3249/4885CA1 1631/4885CA2 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.